• 1
    National Nosocomial Infections Surveillance System. National Nosocomical Infections Surveillance System report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control. 2002; 30: 458475.
  • 2
    Basustaoglu AC, Gun H, Saracli MA, Baysallar M, Haznedaroglu T. Development of resistance to imipenem among nosocomial isolates of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 1995; 14: 469470.
  • 3
    Burwen, DR, Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System. J Infect Dis. 1994; 170: 16221625.
  • 4
    Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis. 1997; 25: 10941098.
  • 5
    Fish DN, MacLaren JR, Obritsch R. Surveillance for multidrug-resistance among clinical isolates of Pseudomonas aeruginosa from intensive care units (ICU) in the United States, 1993–2002. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: American Society for Microbiology, 2003 [presentation].
  • 6
    Carmeli Y, Troillet N, Karchmer A, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 1999; 159: 11271132.
  • 7
    Douglas MW, Mulholland K, Denyer V, Gottlieb T. Multidrug-resistant Pseudomonas aeruginosa outbreak in a burns unit—an infection control study. Burns. 2001; 27: 131135.
  • 8
    Rossello J, Olona M, Campins M, et al. Investigation of an outbreak of nosocomial infection due to a multiply drug-resistant strain of Pseudomonas aeruginosa. J Hosp Infect. 1992; 20: 8796.
  • 9
    Pitten FA, Panzig B, Schroder G, Tietze K, Kramer A. Transmission of a multiresistant Pseudomonas aeruginosa strain at a German University Hospital. J Hosp Infect. 2001; 47: 125130.
  • 10
    Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med. 1997; 155: 16991704.
  • 11
    Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmei Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis. 1999; 28: 11281133.
  • 12
    Muder RR, Brennen C, Drenning SD, Stout JE, Wagener MM. Multiply antibiotic-resistant gram-negative bacilli in a long-term-care facility: a case-control study of patient risk factors and prior antibiotic use. Infect Control Hosp Epidemiol. 1997; 18: 809813.
  • 13
    Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis. 2001; 32(Suppl 2): S146S155.
  • 14
    Jones ME, Styers SD, Thornsberry D, Weaver MK. Factors associated with trends in antimicrobial susceptibility rates in U.S. clinical isolates of P. aeruginosa from 1999 to 2002. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: American Society for Microbiology, 2003 [presentation].
  • 15
    Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988; 16: 128140.
  • 16
    WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical/Defined Daily Dose system. Geneva: World Health Organization, 2003.
  • 17
    Paterson DL. Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin Infect Dis. 2002; 34: 15641567.
  • 18
    Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis. 2001; 32: 10551061.
  • 19
    Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y, Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis. 2002; 34: 15581563.
  • 20
    Krcmery V Jr., Trupl J, Kunova A, et al. Imipenem-resistant Ps. aeruginosa bacteraemia in cancer patients: risk factors, clinical features and outcome. Bratisl Lek Listy. 1996; 97: 647651.
  • 21
    Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann M-C. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis. 2002; 34: 340345.
  • 22
    Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999; 43: 13791382.
  • 23
    El Amari EB, Chamot E, Auckenthaler R, Pechere JC, Van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis. 2001; 33: 18591864.
  • 24
    Murray SA, Snydman DR. Investigation of an epidemic of multidrug-resistant Pseudomonas aeruginosa. Infect Control. 1982; 3: 456460.
  • 25
    Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991; 115: 585590.
  • 26
    Sanders CC, WE Sanders Jr. Beta-lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin Infect Dis. 1992; 15: 824839.
  • 27
    Paramythiotou E, Lucet JC, Timsit J-F, et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis. 2004; 38: 670677.
  • 28
    Studemeister AE, Quinn JP. Selective imipenem resistance in Pseudomonas aeruginosa associated with diminished outer membrane permeability. Antimicrob Agents Chemother. 1988; 32: 12671268.
  • 29
    Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol. 2001; 3: 255264.
  • 30
    Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol. 2000; 3: 489495.
  • 31
    Senda K, Arakawa Y, Nakashima K, et al. Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems. Antimicrob Agents Chemother. 1996; 40: 349353.
  • 32
    Lauretti L, Riccio ML, Mazzariol A, et al. Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother. 1999; 43; 1584–1590.
  • 33
    Tsakris A, Pournaras S, Woodford N, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol. 2000; 38: 290292.
  • 34
    Poirel L, Naas T, Nicolas D, et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother. 2000; 44: 891897.
  • 35
    Sader HS, Castanheira MR, Gordon M, Walsh KA, Deshpande TR, Jones LM. The emergence of metallo-β-Lactamases (MBL) and increasing carbapenem resistance among P. aeruginosa (PSA) and Acinetobacter spp. (ASP) from bloodstream infections (BSI): report from the SENTRY Antimicrobial Surveillance Program. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: American Society for Microbiology, 2003 [presentation].
  • 36
    Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002; 34: 634640.
  • 37
    Schafer H, Ewig S. Acute exacerbations in chronic obstructive pulmonary disease (COPD)—microbial patterns and risk factors. Monaldi Arch Chest Dis. 2000; 55: 415419.
  • 38
    Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002; 57: 759764.
  • 39
    Monso E, Garcia-Aymerich J, Soler N, et al. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect. 2003; 131: 799804.
  • 40
    Talon D, Mulin B, Rouget C, Bailly P, Thouverez M, Viel J-F. Risks and routes for ventilator-associated pneumonia with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 1998; 157(3 Pt 1): 978–984.
  • 41
    Rello J, Ausina V, Ricart M, et al. Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia. Intensive Care Med. 1994; 20: 193198.